Last reviewed · How we verify
efanesoctacog alpha
Efanesoctacog alpha is a recombinant fusion protein that bridges Factor IXa and Factor X to restore the intrinsic tenase complex activity in patients with hemophilia B.
Efanesoctacog alpha is a recombinant fusion protein that bridges Factor IXa and Factor X to restore the intrinsic tenase complex activity in patients with hemophilia B. Used for Hemophilia B (Factor IX deficiency) for routine prophylaxis and treatment of bleeding episodes.
At a glance
| Generic name | efanesoctacog alpha |
|---|---|
| Sponsor | Versiti Blood Health |
| Drug class | Recombinant fusion protein / Coagulation factor bypass agent |
| Target | Factor IXa and Factor X (intrinsic tenase complex) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
This drug is designed for hemophilia B (Factor IX deficiency) by providing a bypass mechanism that allows Factor IXa to activate Factor X independently of the missing Factor VIII cofactor. It functions as a Factor IXa-Factor X fusion protein, effectively restoring the amplification phase of the coagulation cascade. This approach enables hemostasis without requiring Factor IX replacement or Factor VIII supplementation.
Approved indications
- Hemophilia B (Factor IX deficiency) for routine prophylaxis and treatment of bleeding episodes
Common side effects
- Injection site reactions
- Thrombotic events
- Inhibitor development
Key clinical trials
- Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- efanesoctacog alpha CI brief — competitive landscape report
- efanesoctacog alpha updates RSS · CI watch RSS
- Versiti Blood Health portfolio CI